Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk

Federico Licastro, Steve Pedrini, Cinzia Ferri, Valeria Casadei, Marzia Govoni, Annalisa Pession, Francesca Luisa Sciacca, Fabrizio Veglia, Giorgio Annoni, Massimiliano Bonafè, Fabiola Olivieri, Claudio Franceschi, Luigi Maria Edoardo Grimaldi

Research output: Contribution to journalArticle

Abstract

Plasma levels of α1-antichymotrypsin (ACT) and interleukin-1β (IL-1β) were increased in patients with probable Alzheimer's disease (AD). A common polymorphism within ACT and IL-1β genes affected plasma levels of ACT or IL-1β, and AD patients with the ACT T,T or IL-1β T,T genotype showed the highest levels of plasma ACT or IL-1β, respectively. The concomitant presence of the ACT T,T and IL-1β T,T genotypes increased the risk of AD (odds ratio: 5.606, confidence interval: 1.654-18.996) and decreased the age at onset of the disease.

Original languageEnglish
Pages (from-to)388-391
Number of pages4
JournalAnnals of Neurology
Volume48
Issue number3
DOIs
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk'. Together they form a unique fingerprint.

  • Cite this